The cutting edge of chemistry

The Q4 issue of the Cutting Edge of Chemistry (PDF) newsletter which I produce for ThomsonReuters is now online. In this latest issue:

Organic synthesis scheme showcase – The nutlins were first identified by scientists screening a chemical library at Hoffmann-La Roche. In this article, we showcase a new synthetic route to (-)-nutlin 3 recently developed by Tyler Davis and Jeffrey Johnston of Vanderbilt University, that paves the way into the enantioselective arena of nutlin synthesis.

Scaffolds on the move – A wide range of new skeletons emphasize that novel chemical scaffolds with biological activity underpin major advances in medicinal chemistry.

New molecular modes of action – New molecular mechanisms of action are disclosed for a variety of indications.

The starting line – This issue includes drugs related to diabetes, cancer and other conditions such as Graves’ disease and multiple sclerosis.

Downsizing pharma and upgrading collaborations – In this report, we look at how the downsizing pharmaceutical industry is generating new opportunities for the smaller biotechnology and discovery companies. Collaborations between large pharma companies and these smaller enterprises, and even university departments and their spin-off companies, can help cut the overall risk exposure as well as lower investment costs significantly through a focus on developing only those drugs emerging from small laboratories that already show a great deal of clinical promise.

If you enjoyed the newsletter, you might also like my report commemorating the 2011 International Year of Chemistry, entitled “The Changing Role of Chemistry in Drug Discovery“, also available as a free PDF download. The report explores the current state of the pharma and reports the views of several key pharmaceutical industry players, examining how life in drug discovery has changed and how it will continue to change and adapt in the future.

The changing role of the pharma industry

The role of the drug discovery chemist has changed significantly over the past 50 years – workflows have been reinvented while the same goals remain to find and test novel molecules that can reach and act on disease targets.

In this, the International Year of Chemistry (IYC 2011), Thomson Reuters offers a timely report, written by David Bradley with research by Robert Slinn, that examines how life in drug discovery has changed and how it will continue to change and adapt in the future. The report analyzes and develops the major themes identified and highlighted by key players in the global pharmaceutical industry. Many of their insights are fully supported by analysis of data taken from the Thomson Reuters Integrity SM drug discovery database for the period 2001-2011.

In this report, we ask who will emerge as the major drug discoverers and the major drug developers during the next decade. What is the driver for change in the industry and will globalization and regulation have far reaching consequences for the role of the chemist? How will the numbers stack up in 2020 when we count the number of new chemical entities (NCEs): will the balance shift from conventional small molecule Pharma products to the burgeoning area of biologicals?

Future skills

We will discuss how the future skills base will evolve and whether or not there will be a shift in the balance of traditional disciplines. We will calculate the ratelimiting steps and ask if that will affect changing role of chemists. Does a dearth of experience in Pharma, biotech, or academia impact on the changes and what role, if any, might the professional bodies play in the future development of the industry.

TR IYC2011 report available as a PDF here.

Improving century-old chemistry of Haber-Bosch

It is a perennial on almost every chemistry course: the Haber-Bosch process for making ammonia. A potassium-doped iron catalyst is heated to several hundred degrees and high pressure nitrogen and hydrogen gas mixed over it to generate ammonia, which is then fed into fertiliser production. The H-B process very effectively traps and fixes nitrogen from the air, and is the industrial equivalent of nitrogen fixation by legumes and living other plants. The process, first demonstrated in 1909, has fed millions of people through the agricultural revolution of the twentieth century. You might say it has allowed our species to become so successful that it now numbers 7 billion…

However, that high temperature, even taking into account the industrial chemical engineer’s need for good quality “waste” heat for distillation towers and the like, is still wasteful. Catalysts that operate at a much lower temperature would be useful. It would also be useful if they could be dissolved rather than being solids, that would improve efficiency considerably given that the bottleneck in the H-B process is the release of nitrogen from the catalyst surface.

I just covered research from Patrick Holland and colleagues at the University of Rochester, New York, USA and the Max-Planck-Institut für Bioanorganische in Mülheim an der Ruhr, Germany, who have developed an iron compound that can promote the H-B process. You can read my full report on the research this week in Chemistry World.

Holland told me a bit more about his hopes for the research:

“I can envision two possibilities [in enhancing the energy efficiency of the H-B process],” he told me. “First, the structural information from our compounds could be used to design new solid surfaces for the H-B catalyst. In this way, we help surface scientists to formulate useful targets for the synthesis of solid catalysts. Secondly, if we could ultimately tune our solution complexes to make a catalyst that turns over many times in solution at room temperature, then it would reduce the high temperatures and pressures that are currently needed in the H-B process.”

I was curious as to what benefits such a catalyst might have over the standard catalysts that have been used and optimised over the last 100 years. “The high temperatures and pressures used in the H-B process place severe requirements on the factory,” Holland added, “after all, they use high-pressure hydrogen at hundreds of degrees Celsius! It is interesting to consider the reasons for these extreme conditions. The H-B process has a delta-G near zero, so the process is thermodynamically feasible but the rate of catalysis is slow. The reason it must be heated is to give an acceptable rate. Because the Haber-Bosch process is entropically unfavourable, the equilibrium becomes unfavourable at a high temperature unless the pressure is raised. So, the only reason for the high pressure is the high temperature that is needed for catalysis! A faster catalyst would work at lower temperatures, and require lower pressures too.”

There are several obstacles to surmount before a new low-temperature catalyst is ever available for ammonia production. “The current obstacles are that we need to make the final hydride product bind dinitrogen to ‘turn over’ [catalytically speaking] and secondly we need to increase the yields of the nitrogen and hydrogen reactions,” Holland told me. He adds that, “We have other related hydride complexes that can be converted into dinitrogen complexes, and so the situation is hopeful with respect to the first point. We are optimistic that by tuning the supporting ligands we can solve both of these problems and converge on a catalytic system.”

Research Blogging IconMeghan M. Rodriguez, Eckhard Bill, William W. Brennessel, Patrick L. Holland (2011). N2 Reduction and Hydrogenation to Ammonia by a Molecular Iron-Potassium Complex Science, 334, 780-783 : 10.1126/science.1211906

CSI Chemistry – the crime scene

I recently wrote about how Raman spectroscopy could change the way forensic scientists analyse splashes and stains during a crime scene investigation or a suspect’s clothes and skin. Last year, it was saliva analysis, most recently the research has focused on female bodily fluids associated with the scene of a sexual assault or rape. The work is that of Igor Lednev’s team at University at Albany, SUNY, New York. They have now added near-infrared Raman microspectroscopy and an advanced statistical analysis to the arsenal of techniques available to law enforcement scientists allowing them to quickly and accurately identify traces of vaginal fluid at a crime scene, on suspect clothing or skin.

Team member created several montages to illustrate my article, but obviously there was not space for all of them in the published version, so I am reproducing them here. They’re very, very good.

Research Blogging IconSikirzhytskaya, A., Sikirzhytski, V., & Lednev, I. (2011). Raman spectroscopic signature of vaginal fluid and its potential application in forensic body fluid identification Forensic Science International DOI: 10.1016/j.forsciint.2011.08.015

 

Four reasons why open pharma might succeed

During the last decade or so (coincident with the development of open access journal PLoS One, as it happens), the paradigm of “open”, as in open innovation, has changed the way R&D is organised and run in countless high-technology firms. However, the open innovation model has to be adapted and modified to fit specific areas. French researchers have now surveyed managers across the UK’s biopharmaceutical sector at the small-medium enterprise (SME) level to identify what needs to be improved to open innovation still further.

Calin Gurau and Frank Lasch of the GSCM-Montpellier Business School, explain that closed innovation is the classical business model, the one in which a company carries out its R&D and market research entirely in secret, allowing no other eyes to see the products heading for patent and locking down any sub-contractors with tyrannical non-disclosure agreements. Open innovation, on the hand, has emerged as markets and technology have changed. The team points out that the biopharmaceutical sector has developed significantly in the last 30 years.

Until the 1970s, innovation was the realm of big pharma, but access by SMEs and academic spin out companies to relatively inexpensive instrumentation and robotic equipment has meant that almost anyone with a small army of PhDs can innovate to some degree. Similarly, as academics turned to wealth creation so many of the brightest individuals in the corporate world jumped ship to create their own start-ups with a similar thought in mind. It was not quite kitchen bioscience, but the post-genomic era gave another boost to SMEs hoping to get on the pharma ladder and nip at the ankles of the multinationals.

Of course, it quickly became apparent, as it did in the dot.com era, that SMEs cannot necessarily cover all aspects of R&D to compete with big pharma. Thus emerged the open innovation concept. The bright young things whether emerging fresh from academia or shrugging off the corporate cocoon began to realise that their skills could be better served and make them more money by engaging in collaborations with big pharma to provide complementary resources to finalise the R&D operations and bring high-value products to market.

Gurau and Lasch suggest that there are four reasons why open innovation was not only inevitable but essential to the ongoing success of the industry as a whole:

  1. The complexity of the innovation, necessitating resources that cannot be developed internally by a single organisation
  2. The dynamics of competition forces the organisation to accelerate the innovation process
  3. The risk of innovation, which requires a combination of expertise and flexibility that can be often realised only through the collaboration of various highly specialised firms in an innovation network
  4. The specific innovative conditions that cannot be reproduced in large organisations

The (un)conventional perspective on open innovation in pharma is that it works in a similar way to the open source software movement. This model is already in place. Researchers participate and have the right to use freely the discoveries developed within the group, but also being obliged to make freely available to the group any improvement they make to the initial innovation. The Australian non-profit organisation Cambia is a good example of an open innovator as is Open Notebook Science (albeit with a greater academic focus). The website Innocentive.com, initially an initiative of the pharmaceutical company Eli Lilly about which I wrote in my Catalyst column on ChemWeb.com back in the early 2000s, represents an example of an open market for innovative solutions.

A third approach to open innovation sees adaptation of the value co-creation concept in which value is exchanged as a partnership between two parties evolves. The exchange process can sometimes determine the gradual development of a relationship that transforms the open exchange process into a stable business relationship, the researchers suggest.

“The issue of open innovation is particularly significant for the SMEs from high-technology sectors. In the biopharmaceutical sector, the length and the complexity of the R&D process, coupled with the low level of resources of small biotech firms, forces these organisations to search outside sources of innovative expertise and technology,” the researchers conclude.

Research Blogging IconCalin Gurau, & Frank Lasch (2011). Open innovation strategies in the UK biopharmaceutical sector Int. J. Entrepreneurial Venturing, 3 (4), 420-434

2011 Nobel Prize in Chemistry

The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry for 2011 to Daniel Shechtman
Technion – Israel Institute of Technology, Haifa, Israel “for the discovery of quasicrystals”

I got my tweet out seconds before NobelPrize_org and certainly before the rest of the chemistry blogosphere. Sad or what?

In quasicrystals, we find the fascinating mosaics of the Arabic world (see my Alhambra photos for examples) reproduced at the level of atoms: regular patterns that never repeat themselves. However, the configuration found in quasicrystals was considered impossible, and Daniel Shechtman had to fight a fierce battle against established science. The Nobel Prize in Chemistry 2011 has fundamentally altered how chemists conceive of solid matter.

Full Nobel Chemistry press release here.

UPDATE: Shechtman is 70 years old and his work is one of the first times we can date a Nobel-winning scientific discovery to a specific day in 1982. Committee is hoping to speak to him by phone, but they cannot get hold of him right now.

Quasicrystal patterns that are infinite and do not fit the normal requirements of regular solid, crystal structure, has revolutionised our view of solid matter over the years. It shook the foundations of solid-state science. The discovery has actually left us knowing less than we knew before the discovery. It changed the concept of crystallinity. We now do not know what constitutes a crystal. Indeed, we only have an operational definition now the defines a crystal as a solid that produces a diffraction pattern under X-ray irradiation. Regularity no longer comes into it. (To paraphrase committee member Sven Lidin).

UPDATE: Just had word from Professor David Phillips, President of the Royal Society of Chemistry: “Quasicrystals are a fascinating aspect of chemical and material science — crystals that break all the rules of being a crystal at all!” he says. “They’re quite beautiful, and have potential applications in protective alloys and coatings. The award of the Nobel Prize to Dany Shechtman is a celebration of fundamental research.”

John Cleese does chemistry

The Case of the Sulphuric Acid plant was an educational short movie from 1976 aimed at schools and has as its narrator, Monty Python cast member John Cleese, who also features in animated form thanks to the late, great Tony Hart (of Vision On, Take Hart fame). The movie clip was posted on Youtube by the Royal Society of Chemistry recently after a long-lost reel was tracked down by Eton College and with the permission of ccopyrihht holder Akzo Nobel with legal lubrication by Wendy Warr, apparently. As the title would suggest it tells the tale of a sulfuric acid plant (current IUPAC spelling has f not ph, by the way).

Yes, sadly, I am old enough to recall seeing this short movie in school some time in the 1970s (I would have still been in junior school when it was first released, so I suspect it was shown in high school in the late 1970s, just for the record).

This video was viewed 809 times 4th August 2011, 1740 by 10th September. 3415 as of 31st January 2012.

Edible cat litter for drug delivery

Edible cat litter for drug delivery – Having published a bog about bulldogs and cats, seems quite apt that I was also writing recently about kitty litter the main component of which is the absorbant mineral sepiolite. Sepiolite has been known since Roman times when it was used to filter and purify wine, today it's commonly found in cat litter trays. It absorbs huge amounts of liquid as it is so porous although a detailed understanding was missing. Now, an X-ray study could help explain why and perhaps lead to more technological applications, such as the development of food binders and drug-delivery agents.

Science across the spectrum

Penrose, Escher, back – M.C. Escher’s famously paradoxical illustration of 1960 depicting a stairway atop an “impossible” building, and made famous recently in a dreamscape of the Hollywood movie “Inception”, that seems to ascend or descend interminably is a good example of how projecting our 3D world into two dimensions in artwork can be exploited to manipulate our perceptions. The stairway was originally conceived by father and son team Lionel and Roger Penrose in 1959. Now, Japanese chemists have reconstructed the illusion using a single molecule.

Yet another source of antioxidants, in the trees – Researchers in France explain how several species of poplar tree have been used in traditional medicine for their anti-inflammatory properties. They have investigated the sticky fluid that coats poplar buds and demonstrated the presence of various phenolic compounds, terpenoids, flavonoid aglycons and their chalcones and phenolic acids and their esters. The antioxidant potential of these substances might one day be exploited in skincare products or dietary supplements. Once the marketing departments “twig” the benefits, the advertisers will really be able to branch out as long as they can stil see the wood for the trees.

Cystitis clue – UK scientists have revealed the structure of a complex protein called FimD that acts as an assembly platform for the pili of the bacteria that cause cystitis. The structure of the FimD protein means scientists reveals, for the first time, how these pili “hairs” are assembled from individual protein subunits to complete structures. The work offers up a new target for antibiotic drug design.

Taking the lead – It is illegal to use lead as an additive in the manufacture of pewter kitchenware, tableware, drinking cups. However, work in Brazil using atomic absorption spectroscopy not only provides a benchmark for standardizing tests for lead, cadmium and other toxic metals, but reveals that some manufacturers are flouting the law.

 

  • Molecular illusions and deceptions. Ascending and Descending Penrose stairs. (Henry Rzepa)
  • Escher-Inspired Origami
  • Blog – Beyond Escher: The Art Of Tesselation Revealed

Scerri stuff indeed

Scerri stuff indeed – Non-chemists, and perhaps a few chemists, might have assumed that once all the holes in Mendeleev's Periodic Table were filled with modern discoveries and the lanthanides and actinides added, that the Table was forever immutable, a stone tablet to adorn high school chemistry lab walls, textbooks and websites unchanged forever more…well they'd be wrong, some chemists think it's time for a change.